Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
Helsinn Grants Exclusive Licensing Rights to Berlin-Chemie Menarini, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region
Lugano, Switzerland and Berlin, Germany, January 27, 2020 : Helsinn Group (“Helsinn”), a Swiss pharmaceutical group focused on building quality cancer care products, has granted exclusive licensing rights to commercialize A...
Menarini’s Sustenium product line launched on Tmall
Menarini Consumer Healthcare  has entered a partnership with  Alibaba , one of the world’s leading technology companies, by opening a  flagship store on Tmall
61st ASH Congress 2019: Menarini Ricerche presents the latest updates about the First In Human clinical trial of SEL24/MEN1703
Menarini Ricerche is progressing with the clinical development of SEL24/MEN1703, and will be presenting the design of the ongoing First In Human clinical trial DIAMOND-01 (NCT03008187) at the 61 st  ASH Congress
The delicate artistry of Fra Angelico is now a part of the Menarini Art Series
Fra Giovanni da Fiesole, known to the world as Fra Angelico, "Angelic friar”, truly believed that each brush stroke came from...
Press Release
Page available only in italian language 
The Menarini Group announces meropenem/vaborbactam European marketing authorization
Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections. The first combination of a carbapenem and a beta-lactamase inhibitor...
Page 1 of 2First   Previous   [1]  2  Next   Last